Revance Therapeutics (RVNC) Tops Q3 EPS by 6c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/25/2026
- Nasdaq futures surge 2% as chip outlook calms AI jitters; inflation data awaited
- Micron posts record profit as AI memory demand fuels explosive growth
- Brent settles at lowest since before start of Iran war as more tankers exit Hormuz
- IBM surges on unveiling sub-1nm chip technology breakthrough
- 'Long-term deals significant positive for stock:' Analysts react to Micron results
Revance Therapeutic (RVNC) PT Lowered to $42 at Mizuho Securities
November 2, 2018 7:25 AM EDTMizuho Securities analyst, Difei Yang, lowered the price target on Revance Therapeutic (NASDAQ: RVNC) to $42.00 (from $48.00) while maintaining a Buy rating following the company's 3Q earnings report. Revance reported 3Q EPS of $(0.91) that is slightly above FactSet consensus of $(0.92). $2.4 mil of revenue was... More
